AI-designed drug turns back biological age in phase 2a trial

If someone told you that taking a lung disease medication could literally roll back your biological clock by several years, you would probably brush it off as longevity snake oil.

Yet that exact readout just landed in Nature Biotechnology. A post-trial proteomic analysis reveals that an AI-designed drug candidate, rentosertib, delivered measurable anti-aging effects alongside disease control in a randomized phase 2a clinical trial.

Rentosertib, formerly known as INS018_055, is a TNIK inhibitor developed for idiopathic pulmonary fibrosis (IPF). But because TNIK sits right at the intersection of several cellular hallmarks of aging, the team designed the trial from day one to see if treating the lung condition could simultaneously slow systemic aging.

Reading the blood clock

Measuring whether someone is getting younger has always been notoriously messy. DNA methylation clocks often give inconsistent, hard-to-interpret readouts across different cohorts.

Instead, the researchers tracked serum proteins, which directly reflect current cellular activity. They pitted six different proteomic aging clocks against blood samples collected from 42 IPF patients across 21 clinical sites in China.

The results were remarkably consistent. Across all six clocks, treated patients experienced a significant drop in predicted biological age. Placebo patients showed flat or slightly increasing ages over the 12-week study.

The peak effect hit around week 4. On average, patients shed 2 to 3 years in overall biological age, specifically registering decreases between 2.71 and 3.46 years. Organ-specific clocks saw predicted arterial vascular age drop anywhere from 6.95 to 16.57 years.

By week 12, the pace of biological age reduction plateaued rather than continuing to plunge indefinitely, but the systemic shift remained evident.

Separating disease from aging

There is an obvious scientific catch here. Because these participants suffered from severe lung fibrosis, improving their lung function naturally reduced systemic inflammation, which makes blood markers look healthier on paper.

The authors openly concede that you cannot fully decouple anti-fibrotic benefits from true systemic rejuvenation within an IPF cohort. Proving pure anti-aging efficacy will require running trials in healthy volunteers.

Even so, molecular pathway analysis revealed notable shifts in cellular senescence and metabolic regulation that extended beyond basic lung repair, suggesting rentosertib really is modulating broad aging mechanisms.

Why it matters

The real breakthrough here is not a fountain of youth pill, but a regulatory playbook that the longevity field desperately needed.

Global regulators like the FDA do not recognize aging as a treatable disease, making it virtually impossible to sponsor clinical trials solely focused on extending lifespan. Biotech startups have spent years agonizing over how to finance and test longevity compounds under current rules.

This trial offers a proven blueprint for dual-purpose trial design. Drug developers can target serious, approved conditions like fibrosis while quietly embedding proteomic aging endpoints into secondary analyses.

For patients and longevity watchers, this does not mean you can buy an anti-aging drug next month. Rentosertib still has a long road of phase 3 trials ahead. What it does prove, however, is that AI target discovery combined with proteomic tracking can catch tangible biological rejuvenation inside real human bodies.